Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
Pentixapharm Holding AG (Frankfurt Prime Standard:PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced that it has received the formal written minutes from its recent scientific advice meeting with the U.S. Food and Drug Administration (FDA) for the planned Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor, the company's leading CXCR4-directed flagship program. The PANDA study will evaluate the radiodiagnostic...
Read more









